Literature DB >> 2804381

Serological confirmation of human T-lymphotropic virus type I infection in healthy blood and plasma donors.

D W Anderson1, J S Epstein, T H Lee, M D Lairmore, C Saxinger, V S Kalyanaraman, D Slamon, W Parks, B J Poiesz, L T Pierik.   

Abstract

We wished to develop criteria for serological confirmation of human T-lymphotropic virus type I (HTLV-I) infection in healthy donors. Selected serum or plasma samples reactive by HTLV-I enzyme immunosorbent assay or gel-agglutination assays with at least one viral-specific band on Western immunoblot (WIB) were tested in six laboratories by four WIBs and four radioimmunoprecipitation assays (RIPAs) for antibodies to HTLV-I proteins encoded by gag (p19 and p24), env (gp46 and/or gp61), and tax (p40x) genes. One hundred forty-two donor sera were obtained from 38 Japanese, 69 American, and 35 Caribbean blood or plasma donors. Among these samples, WIB assays appeared more sensitive to p24 antibodies, whereas RIPAs were significantly more sensitive to gp61 antibodies. All sera (137) with gp61 antibodies had p24 antibodies. Of the 137 sera positive for p24 and gp61 antibodies, p19 antibodies were detected in 129 sera, and p40x antibodies were detected in 108. In sera with p19 antibodies and antibodies to env- or tax-encoded proteins, p24 antibodies were always present. Antibodies to p40x were not found in the absence of gp61 antibodies. Virological evidence of infection was found in seven American donors by lymphocyte coculture (one HTLV-I, one HTLV-II) or by polymerase chain reaction (three HTLV-I, two HTLV-II). Sera from all seven donors showed p24 and gp46 and/or gp61 antibodies. We suggest that seroreactivity to both p24 and gp46 and/or gp61 by WIB or RIPA or both are suitable criteria to confirm but not to distinguish HTLV-I and HTLV-II infections.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2804381

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Improvement of simultaneous detection of antibodies to Gag and envelope antigens of human T-lymphotropic virus type I by western immunoblot assay.

Authors:  H Miyakoshi; M Sugimoto; H Igarashi; H Honda; R Fujino; M Mizukoshi
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

2.  Evaluation of a recombinant human T-cell lymphotropic virus type I (HTLV-I) p21E antibody detection enzyme immunoassay as a supplementary test in HTLV-I/II antibody testing algorithms.

Authors:  T M Hartley; G E Malone; R F Khabbaz; R B Lal; J E Kaplan
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

3.  Comparison of Western immunoblot antigens and interpretive criteria for detection of antibody to human T-lymphotropic virus types I and II.

Authors:  D Gallo; J L Diggs; C V Hanson
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

4.  Characterization of antibody reactivity to human T-cell lymphotropic virus types I and II using immunoblot and radioimmunoprecipitation assays.

Authors:  T M Hartley; R F Khabbaz; R O Cannon; J E Kaplan; M D Lairmore
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

Review 5.  Serodiagnosis for tumor viruses.

Authors:  Brian J Morrison; Nazzarena Labo; Wendell J Miley; Denise Whitby
Journal:  Semin Oncol       Date:  2014-12-31       Impact factor: 4.929

6.  Evaluation of a solid-phase immunoassay for the simultaneous detection of antibodies to human immunodeficiency virus type 1 and human T-cell lymphotropic virus type I.

Authors:  R A Montagna; L Papsidero; B J Poiesz
Journal:  J Clin Microbiol       Date:  1991-05       Impact factor: 5.948

7.  Isolation and confirmation of human T-cell leukemia virus type 2 from peripheral blood mononuclear cells.

Authors:  Michael D Lairmore; Andy Montgomery
Journal:  Methods Mol Biol       Date:  2005

8.  Synthetic peptide-based immunoassays for distinguishing between human T-cell lymphotropic virus type I and type II infections in seropositive individuals.

Authors:  R B Lal; W Heneine; D L Rudolph; W B Present; D Hofhienz; T M Hartley; R F Khabbaz; J E Kaplan
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

9.  Genetic heterogeneity in human T-cell leukemia/lymphoma virus type II.

Authors:  D K Dube; M P Sherman; N K Saksena; V Bryz-Gornia; J Mendelson; J Love; C B Arnold; T Spicer; S Dube; J B Glaser
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

10.  Prevalence of antibody to human T-cell lymphotropic virus type I/II in people of Caribbean origin in Toronto.

Authors:  J Chiavetta; J Nusbacher; F Tam; A Wall; J Steaffens; H Lee
Journal:  CMAJ       Date:  1992-11-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.